The $5M Round: Is There a Magic Number for Healthcare Startups?
By Samantha McGrandy, CFO at HealthX Ventures
The HealthX team has recently been thinking about our impact over the years across our four funds and 50+ portfolio companies. As we looked more closely at those outcomes, one question kept coming up: How much capital does it take to meaningfully improve a company’s odds of reaching a successful exit?
Our initial investments range from $500k to $4M, excluding follow-on capital. Across our portfolio and the broader venture data, $5M raised in a single round appears to be an important benchmark. For many startups, it can provide the runway needed to prove demand and establish the traction required to reach the next stage.
But the capital itself is only part of the story. The ability to raise $5M can also signal that a founder or leadership team knows how to sell a vision, build confidence, and create momentum. Those same skills matter well beyond fundraising.
So, is $5M actually the threshold? And if it is, how much of the improved outcome comes from the capital itself, how much comes from the company capable of raising it, and how much comes from the support provided along the way?
What the Data Tells Us
Recent fundraising data gives some support to $5M as a meaningful benchmark. Carta describes Seed rounds as generally ranging from about $500k to $5M, with a median Seed raise of $3.5M in 2024. Series A begins around the same $5M mark, with rounds in recent years generally ranging from $5M to $15M and a median Series A raise of $7.9M in Q1 2025.
That puts $5M near the point where a company moves from early validation into a stage where investors increasingly expect evidence of traction, market viability, and a scalable business model. Carta specifically describes Series A companies as typically having demonstrated early traction before raising institutional capital.
The market is also becoming more selective. Carta reported that startups raised nearly $120B in 2025, even as the total number of rounds fell to a six-year low, meaning more capital was concentrated into fewer financings. In that environment, successfully raising a meaningful round can itself say something about the company and management team behind it.
The data does not establish $5M as a universal line between success and failure. However,combined with what we see across our own portfolio, it makes $5M a practical threshold worth exploring.
What $5M Buys in Healthcare
Let’s dig a little deeper into what $5M can buy in healthcare. Healthcare SaaS companies often need more runway than other software businesses. Long sales cycles, regulatory requirements, reimbursement, security reviews, integrations, and slow pilot-to-contract conversions can delay the proof points needed for the next round. That makes the capital threshold less about raising the largest possible round and more about raising enough to absorb delays, convert pilots, close customers, and reach durable milestones. The difference between a $3M and $5M raise may give a company the time needed to move from a promising product to a business with repeatable traction.
There is a limit to that logic. More money is not automatically better. A 2025 analysis published by Crunchbase cautioned that taking too much capital early can reduce flexibility and create an environment where overspending becomes easier, particularly when the capital comes with a valuation the company then has to grow into. Recent Carta data also shows early-stage round sizes and valuations climbing, reinforcing the importance of matching the amount raised with what the business can realistically support.
For founders, the goal should not be to raise $5M simply to clear an arbitrary line, or to raise as much as the market will give them. It should be to raise enough to support the company through the realities of building in healthcare while maintaining the discipline to deploy that capital well.
Capital Creates Runway. Support Shapes Outcomes.
At HealthX, we have watched this play out directly across our portfolio. Several companies faced moments when the most likely outcome could have been failure. The issue may have been a runway gap, a delayed fundraise, a customer relationship at risk, an M&A process that became more complicated than expected, or a cap table that needed to be restructured to keep the company financeable.
Additional capital was often part of the solution, but it was rarely the entire solution. Supporting these companies meant reviewing monthly metrics to identify problems early, helping management understand and extend runway, navigating bridge financings and strategic alternatives, and remaining engaged through difficult operating and board-level decisions.
In some cases, the work was less about accelerating growth and more about mitigating enough risk to keep the company alive. An additional 6 or 12 months of runway can give a team the time needed to reach its next critical milestone.
That value is difficult to capture in a data set. Research can measure dollars raised, funding stages, and exit outcomes. It cannot easily measure the late-night call helping a founder through M&A negotiations, the board discussion that prevents a cash crisis, or the monthly review that identifies where the holes may be and where an investor can be a resource.
Our internal research and portfolio analysis suggest that the more meaningful threshold is a combination of raising at least $5M in a single round, choosing the right investors, and remaining disciplined in how the capital is deployed.
Reaching that threshold may create the opportunity. Using it well is what turns the opportunity into an outcome.